Please login to the form below

Not currently logged in
Email:
Password:

Letermovir

This page shows the latest Letermovir news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

EC grants MSD’s Prevymis orphan product designation

The status for Prevymis’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). ... to help ensure that appropriate patients

Latest news

  • CHMP backs MSD’s CMV infection treatment CHMP backs MSD’s CMV infection treatment

    Merck Sharp &Dohme (MSD) is closing on European approval for its infection treatment Prevymis (letermovir) after it received backing from the Committee for Medicinal Products for Human Use’s (CHMP) last ... The US Food and Drug Administration approved

  • Merck says drug for CMV in transplant patients hits targets Merck says drug for CMV in transplant patients hits targets

    Letermovir on course for fast-track 2017 filing and head start in prospective $350m market. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked for fast-track review by the FDA.

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    CMV) and related assets. Letermovir has orphan drug status in the EU and the US, where it has also been granted fast track designation. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase IIb) and antiviral portfolio for CMV.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics